CN116997337A - 半乳糖缺陷型免疫球蛋白的双官能降解剂 - Google Patents

半乳糖缺陷型免疫球蛋白的双官能降解剂 Download PDF

Info

Publication number
CN116997337A
CN116997337A CN202280020292.8A CN202280020292A CN116997337A CN 116997337 A CN116997337 A CN 116997337A CN 202280020292 A CN202280020292 A CN 202280020292A CN 116997337 A CN116997337 A CN 116997337A
Authority
CN
China
Prior art keywords
optionally substituted
group
groups
moiety
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280020292.8A
Other languages
English (en)
Chinese (zh)
Inventor
G·M·杜博奇克
D·施皮格尔
R·M·坎德韦尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baiaohaifen Therapeutics Co ltd
Original Assignee
Baiaohaifen Therapeutics Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baiaohaifen Therapeutics Co ltd filed Critical Baiaohaifen Therapeutics Co ltd
Publication of CN116997337A publication Critical patent/CN116997337A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280020292.8A 2021-03-10 2022-03-10 半乳糖缺陷型免疫球蛋白的双官能降解剂 Pending CN116997337A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163159383P 2021-03-10 2021-03-10
US63/159,383 2021-03-10
PCT/US2022/019658 WO2022192478A1 (en) 2021-03-10 2022-03-10 Bifunctional degraders of galactose-deficient immunoglobulins

Publications (1)

Publication Number Publication Date
CN116997337A true CN116997337A (zh) 2023-11-03

Family

ID=83227063

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280020292.8A Pending CN116997337A (zh) 2021-03-10 2022-03-10 半乳糖缺陷型免疫球蛋白的双官能降解剂

Country Status (11)

Country Link
US (2) US20240309114A1 (cg-RX-API-DMAC10.html)
EP (1) EP4304579A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024509282A (cg-RX-API-DMAC10.html)
KR (1) KR20230154900A (cg-RX-API-DMAC10.html)
CN (1) CN116997337A (cg-RX-API-DMAC10.html)
AU (1) AU2022232620A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023017702A2 (cg-RX-API-DMAC10.html)
CA (1) CA3211335A1 (cg-RX-API-DMAC10.html)
IL (1) IL305665A (cg-RX-API-DMAC10.html)
MX (1) MX2023010424A (cg-RX-API-DMAC10.html)
WO (1) WO2022192478A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12023553152A1 (en) * 2021-05-17 2024-03-11 Biohaven Therapeutics Ltd Compositions including conjugated therapy enhancers
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス, インコーポレイテッド Asgpr細胞表面受容体結合化合物及びコンジュゲート
CN121038815A (zh) * 2023-04-29 2025-11-28 拜奥海芬治疗学有限公司 半乳糖缺陷型免疫球蛋白的双功能降解剂
WO2026083257A1 (en) 2024-10-14 2026-04-23 Biohaven Therapeutics Ltd. Antigen-specific degraders of immunoglobulin a and their uses
WO2026120177A1 (en) 2024-12-06 2026-06-11 Ascendis Pharma A/S Novel long-acting degrader conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112236169A (zh) * 2018-04-09 2021-01-15 耶鲁大学 靶向循环蛋白质的选择性降解的双功能小分子

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440191B2 (en) * 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
DK2991683T3 (da) * 2013-05-02 2019-11-04 Glykos Finland Oy Konjugater af et glykoprotein eller en glykan med en toksisk ladning
CA2946064C (en) * 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
RU2696490C2 (ru) * 2014-05-19 2019-08-02 Пфайзер Инк. Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112236169A (zh) * 2018-04-09 2021-01-15 耶鲁大学 靶向循环蛋白质的选择性降解的双功能小分子

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JIRI MESTECKY等: "IgA nephropathy enigma", 《CLINICAL IMMUNOLOGY》, 18 July 2016 (2016-07-18), pages 72 - 77 *
YAXIAN ZHOU等: "Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins", 《ACS CENTRAL SCIENCE》, vol. 7, no. 3, 4 March 2021 (2021-03-04), pages 3 *

Also Published As

Publication number Publication date
US20260146106A1 (en) 2026-05-28
JP2024509282A (ja) 2024-02-29
BR112023017702A2 (pt) 2023-12-12
CA3211335A1 (en) 2022-09-15
MX2023010424A (es) 2023-09-18
EP4304579A4 (en) 2026-06-10
US20240309114A1 (en) 2024-09-19
IL305665A (en) 2023-11-01
KR20230154900A (ko) 2023-11-09
WO2022192478A1 (en) 2022-09-15
AU2022232620A1 (en) 2023-09-21
EP4304579A1 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
JP7430643B2 (ja) カンプトテシンペプチドコンジュゲート
CN116196435B (zh) 包含sting激动剂的抗体药物缀合物
JP7241811B2 (ja) 四級化チューブリシン化合物の複合体
CN111163809B (zh) 转谷氨酰胺酶缀合方法和接头
US12187745B2 (en) Camptothecine antibody-drug conjugates and methods of use thereof
RU2728235C2 (ru) Конъюгат антитела и лекарственного средства, композиции на его основе и способы их получения
KR20230154900A (ko) 갈락토스-결핍 면역글로불린의 이중기능성 분해제
KR20230004453A (ko) 캄프토테신 유도체 및 이의 접합체
CN117042806A (zh) 抗体-免疫激动剂缀合物及其应用
CA3166699A1 (fr) Conjugues anticorps-medicament anti-cd56 et leur utilisation en therapie
JP2021528431A (ja) Il−17に結合するためのペプチドリガンド
JP2016050204A (ja) 抗体薬物コンジュゲートと共に使用する安定性調節用リンカー
JP7846624B2 (ja) ペプチド含有リンカーとの部位特異的抗体-薬物コンジュゲート
JP2024506300A (ja) 免疫刺激化合物及びコンジュゲート体
JP2021513990A (ja) 疎水性アウリスタチンf化合物およびそのコンジュゲート
CN113842467A (zh) 用于抗体与药物偶联体(adc)制备的中间体及其制备方法和应用
CN114980932A (zh) Sortilin结合缀合化合物、其组合物及其用于治疗癌症的用途
US20240197907A1 (en) Dual-Cleavage Ester Linkers for Antibody-Drug Conjugates
SK150196A3 (en) Peptides with immunomodulatory effects, pharmaceutical formulations containing them and their use
JP2023551203A (ja) 抗体-薬物コンジュゲートのためのグリコシド二重切断リンカー
KR20240016231A (ko) 신규 오리스타틴 전구약물
WO2026092698A1 (zh) 一种抗体-药物偶联物及其制备方法和用途
WO2025064424A1 (en) Tandem-cleavage linkers for antibody-drug conjugates and uses thereof
CA3227975A1 (en) Antibody conjugates specific for mucin-1 and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination